The claim limitation that defines an incretin-agonist patent is the receptor set. Start with the dual agonists: Lilly's US12295987B2 (GIP/GLP-1, 2025) and BrightGene's US12215133B2 ("GIP and GLP-1 dual receptor agonist," 2025). Both recite activation of two specific receptors. Now add a third: AlbuNext's US12551541B2, "Albumin bound macromolecule tri-agonist activating GLP-1/GIP/glucagon receptors and methods therefor" (issued February 17, 2026; CPC C07K 14/4722), recites a molecule hitting three. The receptor count is the species discriminator.
This is a textbook genus-and-species progression. The broad genus is "incretin-pathway agonists." Within it, GLP-1 mono-agonism is the oldest, widely-practiced species. GIP/GLP-1 dual agonism is a narrower, newer species — claimable because the combination produced a distinct clinical effect. GLP-1/GIP/glucagon triple agonism is narrower still, adding glucagon-receptor activity. Each step down the genus is a fresh species claim, defensible to the extent the added receptor delivers a non-obvious benefit.
Construe the receptor recital strictly, because it controls infringement. A competitor's dual GIP/GLP-1 agonist does not infringe a triple-agonist claim that requires glucagon-receptor activity — the missing receptor reads it out. Conversely, a triple agonist may read on a dual-agonist claim if the dual claim is written openly ("comprising" activation of GIP and GLP-1) such that additional activity does not avoid it. The transitional language and the receptor list together decide the reach.
The added-receptor obviousness question is the live battleground. When a patentee claims the next agonist up — adding glucagon to GIP/GLP-1 — the challenger argues that adding a known receptor's activity was an obvious extension. The patentee argues the specific combination produced unexpected results. So each new species claim invites the same fight: is the additional receptor an inventive leap or an obvious increment over the prior species?
The AlbuNext claim also bundles a delivery feature — "albumin bound macromolecule" — into the agonist claim (it appears in a companion grant, US12576141B2, as well). Coupling a half-life-extension strategy (albumin binding) to the receptor profile narrows the claim but ties two innovations together, a pattern that recurs as the field matures: the pure receptor-profile species claims give way to species claims that also recite delivery or conjugation features.
The construction takeaway: read an incretin-agonist claim by counting and naming its receptors, then checking the transitional language. Dual versus triple is not marketing — it is the species limitation that determines both what infringes and what prior species the claim must be non-obvious over. The genus is old; the value is in the specific, newly-claimed receptor combinations, and each added receptor is a new line in the genus-species map.